Connect Sign In
LabMind podcasts
Utah Business magazine has honored ARUP Laboratories with a 2023 Best Companies to Work For Award. ARUP has earned this award every year since 2018. |
December 1, 2023 |
ARUP Laboratories Honored With 2023 Best Companies to Work For Award From Utah Business Magazine Utah Business magazine honored ARUP Laboratories with its Best Companies to Work For award for the sixth consecutive year based on anonymous employee survey results. |
Jonathan Genzen, MD, PhD (left), chief medical officer and senior director of governmental affairs, and Jonathan Carr, JD (right), compliance officer, prepare for ARUP’s webinar on the FDA’s proposed rule to regulate lab-developed tests. |
November 30, 2023 |
Watch Now: ARUP Experts Host Q&A Session on FDA’s Proposal to Regulate Lab-Developed Tests Days before the public comment period ends, ARUP Laboratories’ experts host webinar to educate and encourage attendees to provide comments on the FDA’s proposed rule to regulate lab-developed tests. |
ARUP Laboratories has released the company’s public comment in response to the FDA’s plan to regulate LDTs. |
November 29, 2023 |
ARUP Laboratories Urges FDA to Withdraw Proposed Rule Regulating Laboratory-Developed Tests ARUP believes the FDA’s plan to regulate lab-developed tests will limit access to testing, increase costs, and face a court challenge, and is calling for collaboration to better address LDT oversight. |
Jonathan Genzen, MD, PhD (left), chief medical officer and senior director of governmental affairs, will lead the webinar, and Jonathan Carr, JD (right), compliance officer, will moderate a Q&A session. |
November 21, 2023 |
ARUP to Host Webinar to Discuss Impacts of the FDA’s Proposed Rule to Regulate Lab-Developed Tests ARUP experts seek to increase understanding of the FDA’s proposed rule to regulate lab-developed tests as medical devices and the impact on hospitals and patients during a webinar on November 29. |
AAV5 DetectCDx™ detects the presence of anti-AAV5 antibodies to aid in the selection of patients eligible for the treatment ROCTAVIAN™. |
November 10, 2023 |
EU Approval of AAV5 DetectCDx™ Provides Access to Companion Diagnostic for Hemophilia A Gene Therapy ARUP has gained a Conformité Européenne (CE) mark for AAV5 DetectCDx™ single-site use. The test will aid in determining the eligibility of non-U.S. patients for a new hemophilia A gene therapy. |
From left, Greg Critchfield, Myriad Genetics and Sera Prognostics; Mark Poritz, Co-Diagnostics; Kyle Berg, Quansys Biosciences; Jared Bauer, Seek Labs; Tracy I. George, ARUP Laboratories; and Andrew Hemmert, bioMerieux. These panelists addressed challenges facing diagnostics companies during a discussion at the Utah Life Sciences Summit in Salt Lake City on November 9. |
November 10, 2023 | A panel discussion at the Utah Life Sciences Summit explored how the FDA’s proposed rule to further regulate laboratory-developed tests could slow advances in diagnostic medicine. |
ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ We accelerate the development and adoption of cutting-edge diagnostic and prognostic technologies advancing patient care through groundbreaking science and engineering. The Sherrie Perkins Research and Innovation Collaboration Grant The Sherrie Perkins Research and Innovation Collaboration Grant funds cutting-edge research in laboratory medicine.
ARUP Newsroom
Live Chat